Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension
Quantum Genomics Provides Update on the Impact of the COVID-19 Health Crisis on Clinical Research Activities
Quantum Genomics Secured New Financing, Published its Financial Statements for Fiscal Year 2019 and Provides 2019 Highlights
Quantum Genomics Initiatesits Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension
Quantum Genomics and Biolab Sanus Pharmaceutical have signed an exclusive agreement for firibastat in Latin America
